Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  European Journal of Pharmacology

• Publication date

  2009-11-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejphar.2009.09.018PMID 19766109
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of sumatriptan on nitric oxide synthase enzyme production after iatrogenic inflammation in the brain stem of adolescent rats: A randomized, controlled, experimental study.

  2009cited by this paper
• The Prototype Serotonin 5-HT1B/1D Agonist Sumatriptan Increases the Severity of Myocardial Ischemia During Atrial Pacing in Dogs With Coronary Artery Stenosis

  2009cited by this paper
• Calcitonin Gene-Related Peptide Receptor Antagonism Does Not Affect the Severity of Myocardial Ischemia during Atrial Pacing in Dogs with Coronary Artery Stenosis

  2009cited by this paper
• Clinical and Preclinical Rationale for CGRP‐Receptor Antagonists in the Treatment of Migraine

  2008cited by this paper
• Crosstalk of vascular 5-HT1 receptors with other receptors: Clinical implications

  2008cited by this paper
• Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

  2008cited by this paper
• Crosstalk of vascular 5-HT1 receptors with other receptors: clinical implications.

  2008cited by this paper
• Calcitonin gene-related peptide (CGRP) antagonists and migraine

  2008cited by this paper
• Investigation of the immunoreactivities of NOS enzymes and the effect of sumatriptan in adolescent rats using an experimental model of migraine

  2008cited by this paper
• Inhibition of Calcitonin Gene‐Related Peptide Function: A Promising Strategy for Treating Migraine

  2008cited by this paper
• Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine

  2008cited by this paper
• Acute myocardial infarction after sumatriptan administration for cluster headache

  2006cited by this paper
• Hyaluronidase treatment of coronary glycocalyx increases reactive hyperemia but not adenosine hyperemia in dog hearts.

  2005cited by this paper
• A Case of Myocardial Infarction with Sumatriptan Use

  2005cited by this paper
• Calcitonin Gene-Related Peptide In Vivo Positive Inotropy Is Attributable to Regional Sympatho-Stimulation and Is Blunted in Congestive Heart Failure

  2005cited by this paper
• Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients

  2005cited by this paper
• Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

  2004cited by this paper
• Vascular actions of calcitonin gene-related peptide and adrenomedullin.

  2004cited by this paper
• Coronary Vasoconstrictor Potential of Triptans: A Review of In Vitro Pharmacologic Data

  2004cited by this paper
• Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on alpha-CGRP-induced regional haemodynamic changes in anaesthetised rats.

  2004cited by this paper
• Effects of Inhibition of &agr;-CGRP Receptors on Cardiac and Peripheral Vascular Dynamics in Conscious Dogs with Chronic Heart Failure

  2003cited by this paper
• Investigation of CGRP Receptors and Peptide Pharmacology in Human Coronary Arteries. Characterization with a Nonpeptide Antagonist

  2003cited by this paper
• Effects of BIBN4096BS on cardiac output distribution and on CGRP-induced carotid haemodynamic responses in the pig.

  2003cited by this paper
• Effects of inhibition of alpha-CGRP receptors on cardiac and peripheral vascular dynamics in conscious dogs with chronic heart failure.

  2003cited by this paper
• Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT(1B) and 5-HT(1D) receptor antagonists and in situ hybridization.

  2002cited by this paper
• Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells.

  2002cited by this paper
• Characterization of Sumatriptan-Induced Contractions in Human Isolated Blood Vessels Using Selective 5-HT1B and 5-HT1D Receptor Antagonists and In Situ Hybridization

  2002cited by this paper
• Functional Role of α-Calcitonin Gene-Related Peptide in the Regulation of the Cardiovascular System

  2001cited by this paper
• Platelet Glycoprotein IIb/IIIa Receptor Inhibitor Preserves Coronary Flow Reserve During Progressive Coronary Arteriostenosis in Swine

  2000cited by this paper
• Effects of antiaggregant and antiinflammatory doses of aspirin on coronary hemodynamics and myocardial reactive hyperemia in conscious dogs.

  1999influential reference
• Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques.

  1999cited by this paper
• Coronary side-effect potential of current and prospective antimigraine drugs.

  1998influential reference
• Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration.

  1998cited by this paper
• Contractile responses evoked by dihydroergotamine, naratriptan and sumatriptan in the canine isolated coronary artery

  1998cited by this paper
• Naratriptan

  1997cited by this paper
• Comparison of the cardiovascular effects of the novel 5-HT(1B/1D) receptor agonist, SB 209509 (VML251), and sumatriptan in dogs.

  1997influential reference
• Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols.

  1997influential reference
• Evidence for 5-HT1D beta but not 5-HT1D alpha receptor subtype expression in canine large coronary arteries and saphenous vein.

  1996cited by this paper
• Vasospasm-induced myocardial infarction with sumatriptan.

  1996cited by this paper
• Coronary and Systemic Hemodynamic Effects of Sustained Inhibition of Nitric Oxide Synthesis in Conscious Dogs

  1996influential reference
• Evidence for 5-HT1Dβ but not 5-HT1Dα receptor subtype expression in canine large coronary arteries and saphenous vein

  1996cited by this paper
• Coronary and systemic hemodynamic effects of sustained inhibition of nitric oxide synthesis in conscious dogs. Evidence for cross talk between nitric oxide and cyclooxygenase in coronary vessels.

  1996cited by this paper
• Effects of U46619 on contractions to 5‐HT, sumatriptan and methysergide in canine coronary artery and saphenous vein in vitro

  1995cited by this paper
• Oral sumatriptan-associated transmural myocardial infarction

  1995cited by this paper
• The in vivo pharmacological profile of a 5‐HT1 receptor agonist, CP‐122, 288, a selective inhibitor of neurogenic inflammation

  1995influential reference
• Effect of calcitonin gene-related peptide on coronary microvessels and its role in acute myocardial ischemia.

  1994cited by this paper
• Transmural myocardial infarction with sumatriptan.

  1993cited by this paper
• Modulation of coronary autoregulatory responses by nitric oxide. Evidence for flow-dependent resistance adjustments in conscious dogs.

  1993cited by this paper
• Peptidergic innervation of human epicardial coronary arteries.

  1993cited by this paper
• 5-HT receptors mediating contractions of the isolated human coronary artery.

  1993influential reference
• Contribution of nitric oxide to dilation of resistance coronary vessels in conscious dogs.

  1992influential reference
• Role of endothelium-derived nitric oxide in myocardial reactive hyperemia.

  1992influential reference
• Effects of Calcitonin Gene‐Related Peptide on Normal and Atheromatous Vessels and on Resistance Vessels in the Coronary Circulation in Humans

  1991cited by this paper
• The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan.

  1991cited by this paper
• Mutual interaction between presynaptic α2-adrenoceptors and 5-HT1B receptors on the sympathetic nerve terminals of the rat inferior vena cava

  1990cited by this paper
• Autoradiographic mapping of calcitonin gene-related peptide receptors in human and guinea pig hearts.

  1990cited by this paper
• The first demonstration of CGRP-immunoreactive fibers in canine hearts: coronary vasodilator, inotropic and chronotropic effects of CGRP in canine isolated, blood-perfused heart preparations.

  1989cited by this paper
• Calcitonin gene-related peptide receptor antagonist human CGRP-(8-37).

  1989cited by this paper
• The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs

  1989influential reference
• Cardiovascular effects of calcitonin gene-related peptides I and II in man.

  1987cited by this paper
• Myocardial reactive hyperemia.

  1975cited by this paper

• A Pharmacological Review of Calcitonin Gene-Related Peptide Biologics and Future Use for Chronic Pain

  2023cites this paper
• CGRP Inhibitors for the Treatment of Migraine

  2021cites this paper
• Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials

  2020cites this paper
• Novel synthetic treatment options for migraine

  2020cites this paper
• Rimegepant in the Treatment of Migraine

  2020cites this paper
• Calcitonin Gene‐Related Peptide Modulators – The History and Renaissance of a New Migraine Drug Class

  2019cites this paper
• Gepants for the treatment of migraine

  2019cites this paper
• Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine.

  2019cites this paper
• From LBR-101 to Fremanezumab for Migraine

  2018cites this paper
• CGRP als therapeutisches Ziel in der Therapie von primären Kopfschmerzen

  2017cites this paper
• Triptans to Calcitonin Gene‐Related Peptide Modulators – Small Molecules to Antibodies – the Evolution of a New Migraine Drug Class

  2017cites this paper
• TEV-48125: a Review of a Monoclonal CGRP Antibody in Development for the Preventive Treatment of Migraine

  2015cites this paper
• Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP

  2014cites this paper
• Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program

  2014cites this paper
• Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide

  2014cites this paper
• BMS-927711 for the acute treatment of migraine

  2014cites this paper
• Calcitonin Gene‐Related Peptide (CGRP) and Migraine Current Understanding and State of Development

  2013cites this paper
• Randomized, Controlled Study of Telcagepant in Patients With Migraine and Coronary Artery Disease

  2012cites this paper
• 10th annual meeting of the Safety Pharmacology Society: an overview

  2011cites this paper
• CGRP receptor antagonists: toward a novel migraine therapy.

  2011cites this paper
• Potential mechanisms of prospective antimigraine drugs: a focus on vascular (side) effects.

  2011cites this paper
• Effect of Telcagepant on Spontaneous Ischemia in Cardiovascular Patients in a Randomized Study

  2011cites this paper
• Possible sites of action of the new calcitonin gene-related peptide receptor antagonists

  2010cites this paper
• Characterization of the Calcitonin Gene-Related Peptide Receptor Antagonist Telcagepant (MK-0974) in Human Isolated Coronary Arteries

  2010cites this paper